GlaxoSmithKline
NEWS
Paris-based Sanofi settled corruption charges with the U.S. Securities and Exchange Commission (SEC) for more than $25 million. Sanofi is far from the first pharma company to be accused of bribery.
Two years after charges were filed by the federal government, former GlaxoSmithKline researcher Yu Xue pled guilty to a single conspiracy charge related to emailing company trade secrets that would have been used to set up competing companies in China.
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let’s take a look.
AstraZeneca and MedImmune announced top-line results from its TULIP 1 Phase III clinical trial of anifrolumab in adults with moderate-to-severe systemic lupus erythematosus (SLE). Unfortunately, the drug didn’t meet the trials primary endpoint of statistically-significant reduction in disease activity.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Nearly two months ahead of the planned PDUFA date, the U.S. Food and Drug Administration approved two new HIV-1 treatments developed by Merck. The FDA gave the go ahead for Delstrigo, a once-per day triple combination treatment and Pifeltro, a new non-nucleoside reverse transcriptase inhibitor.
Changes are coming to the way 23andMe does business. The company will no longer provide “outside app developers” access to the company’s raw genetic data, CNBC reported this morning.
As Brexit creeps closer and closer, the British government, as well as pharmaceutical companies and the European Medicines Agency, are preparing contingency plans for dealing with the possibility that healthcare-related companies will not have contracts in place in time.
AstraZeneca has seen another setback in a late-stage trial for chronic obstructive pulmonary disease (COPD) treatments. The latest stumbling block includes a failure for AstraZeneca’s investigational treatment to distinguish itself from a drug already marketed by rival GlaxoSmithKline.
JOBS
IN THE PRESS